The state of New Jersey currently has 11 active clinical trials seeking participants for Epilepsy research studies. These trials are conducted in various cities, including New Brunswick, Hackensack, Newark and Morristown.
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/20/2025
Locations: NEREG, Hackensack, New Jersey
Conditions: Focal Epilepsy
Register for Updates
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
NCT06425159
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/19/2025
Locations: NEREG, Hackensack, New Jersey +1 locations
Conditions: Generalized Epilepsy
Register for Updates
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
NCT06315322
Recruiting
The purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
08/14/2025
Locations: Ep0224 50638, New Brunswick, New Jersey
Conditions: Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Register for Updates
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
NCT06063850
Recruiting
The main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of seizures in adults with unilateral mesial temporal lobe epilepsy (MTLE).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/24/2025
Locations: Northeast Regional Epilepsy Group, Hackensack, New Jersey +1 locations
Conditions: Mesial Temporal Lobe Epilepsy
Register for Updates
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
NCT05067634
Recruiting
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
07/23/2025
Locations: Northeast Regional Epilepsy Group, Hackensack, New Jersey +1 locations
Conditions: Partial Epilepsy
Register for Updates
Evaluation of the 24/7 EEG SubQ System for Ultra Long-Term Recording of Patients With Epilepsy Involving the Temporal Lobe Region.
NCT04526418
Recruiting
The 24/7 EEG™ SubQ system will be compared to simultaneously recorded video-EEG in the Epilepsy Monitoring Unit (gold standard) and to self-reported seizure log books throughout 12 weeks of outpatient EEG recording. The present study is a 12-week open-label, prospective study with a paired, comparative design for pivotal evaluation of the safety and effectiveness of the 24/7 EEGTM SubQ system in subjects with epilepsy involving the temporal lobe region . 2-5 sites in Europe Up to 10 sites in U... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/09/2025
Locations: Hackensack Meridian Health, Neptune, New Jersey
Conditions: Epilepsy
Register for Updates
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06132893
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/07/2025
Locations: NEREG, Hackensack, New Jersey +1 locations
Conditions: Focal Epilepsy
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
NCT04666610
Recruiting
The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).
Gender:
ALL
Ages:
Between 2 years and 25 years
Trial Updated:
04/10/2025
Locations: N01269 100, New Brunswick, New Jersey
Conditions: Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Register for Updates
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
NCT06908356
Recruiting
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/26/2025
Locations: Praxis Research Site, Hackensack, New Jersey
Conditions: Focal Onset Seizure, Primary Generalized Epilepsy
Register for Updates
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-Onset Seizures
NCT04903314
Recruiting
The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizures following single and multiple-dosing.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
03/03/2025
Locations: Northeast Regional Epilepsy Group, Hackensack, New Jersey +1 locations
Conditions: Partial Epilepsy
Register for Updates
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
NCT04770337
Recruiting
This is a multiple site, randomized, double blinded parallel-group controlled study. The purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers transcranial cathodal direct current stimulation (tDCS). Subjects will be treated with STARTSTIM or sham device for 10 sessions over a 2-week period. The subjects will be followed for an additional 10 weeks post treatment. Quality of Life questionnaires and adverse even... Read More
Gender:
ALL
Ages:
9 years and above
Trial Updated:
11/14/2024
Locations: Robert Wood Johnson Medical School (Rutgers), New Brunswick, New Jersey
Conditions: Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures, Epilepsy in Children, Epilepsy, Epilepsy, Tonic-Clonic
Register for Updates